Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies
Joint Authors
Husayn, Sad Abd al-Rahman
Mishimish, Bahir Abd al-Razzaq
Ismail, Sijidah Husayn
Husayn, Khalid Ibrahim
Sulayman, Amal Ajawid
Source
Journal of the Faculty of Medicine Baghdad
Issue
Vol. 49, Issue 4 (31 Dec. 2007), pp.449-456, 8 p.
Publisher
University of Baghdad Faculty of Medicine
Publication Date
2007-12-31
Country of Publication
Iraq
No. of Pages
8
Main Subjects
Topics
Abstract EN
Background : Many drug and non drug approaches are utilized for the treatment of dyslipidemia ; flavonoids, the major constituents of silymarin, have been proved to positively modify lipoproteins in experimentally-induced dyslipidemia.
Objective : This study was designed to evaluate the effect of silymarin, when used alone or in combination with other hypolipidemic agents, on the lipid profile in dyslipidemic patients.
Fac Med Baghdad Patients and Methods : Fifty seven patients with dyslipidaemia of various etiologies are involved in this clinical trial.
They are randomized into three groups treated with either 400 mg / day silymarin (gr.
A) or 20 mg / day lovastatin (gr.
B) or a combination of 200 mg / day silymarin and 10 mg / day lovastatin (gr.
C) for 2 months, only 45 patients complete the study.
Serum lipid profile (total cholesterol, triglycerides, LDLC, VLDL-C and HDL-C) and liver functions indices (SGOT, SGPT, total bilirubin) were evaluated each month during the follow up period.
Results : Treatment with silymarin results in a significant decrease in TC, TG, LDL-C and VLDL-C levels, with a significant elevation in HDL-C levels, without any significant changes in liver function.
Meanwhile, adjunct use of silymarin with lovastatin widens the scope of lovastatin-hypolipidemic effect, without increasing in the score of adverse effects, and ameliorating the hepatic damage emerged due to its use.
Conclusions : The results presented in this study indicated that silymarin can be used alone in clinical practice for the treatment of dyslipidemia, and when combined with other hypolipidemic agents like lovastatin, improves therapeutic profile and ameliorate some of its adverse effects.
American Psychological Association (APA)
Mishimish, Bahir Abd al-Razzaq& Husayn, Sad Abd al-Rahman& Ismail, Sijidah Husayn& Husayn, Khalid Ibrahim& Sulayman, Amal Ajawid. 2007. Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies. Journal of the Faculty of Medicine Baghdad،Vol. 49, no. 4, pp.449-456.
https://search.emarefa.net/detail/BIM-339232
Modern Language Association (MLA)
Mishimish, Bahir Abd al-Razzaq…[et al.]. Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies. Journal of the Faculty of Medicine Baghdad Vol. 49, no. 4 (2007), pp.449-456.
https://search.emarefa.net/detail/BIM-339232
American Medical Association (AMA)
Mishimish, Bahir Abd al-Razzaq& Husayn, Sad Abd al-Rahman& Ismail, Sijidah Husayn& Husayn, Khalid Ibrahim& Sulayman, Amal Ajawid. Hypolipidemic effect of silymarin in dyslipidaemia of different etiologies. Journal of the Faculty of Medicine Baghdad. 2007. Vol. 49, no. 4, pp.449-456.
https://search.emarefa.net/detail/BIM-339232
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references : p. 455-456
Record ID
BIM-339232